基于分子特征与结局,慢性中性粒细胞白血病与非典型慢性髓性白血病应被视为同一实体
这项国际多中心研究纳入慢性中性粒细胞白血病(CNL)24例与非典型慢性髓性白血病(aCML)37例,比较两者临床与突变特征(53例有分子数据),发现临床表现与结局无差异,仅EZH2与TET2在两者间突变频率不同,支持两者为同一疾病连续谱。
要点
- CNL与aCML临床表现及结局无差异,分子特征支持两者为同一疾病连续谱。
- 除CSF3R外,仅EZH2与TET2在CNL与aCML间存在突变差异。
- 多因素分析识别出CEBPA、EZH2、NRAS、U2AF1四个高风险突变基因。
核心结论
- 分子特征与结局支持CNL与aCML为同一疾病的连续谱,可能最适合归入骨髓增生异常/骨髓增殖性肿瘤(MDS/MPN)。
- 研究结果强调分子风险分类在CNL/aCML中的意义以及CSF3R突变在这些疾病中的重要性。
研究设计与样本
- 国际多中心研究,纳入CNL 24例与aCML 37例,其中53例有分子数据,分析临床与突变特征。
主要发现
- CNL与aCML在临床表现或结局上无差异。
- 两者均具有复杂突变谱,涉及表观遗传调控、剪接与信号通路基因。
- 除CSF3R外,仅EZH2与TET2在两者间存在差异突变。
- 多因素分析识别4个高风险突变基因:CEBPA(β=2.26,HR=9.54,P=.003)、EZH2(β=1.12,HR=3.062,P=.009)、NRAS(β=1.29,HR=3.63,P=.048)、U2AF1(β=1.75,HR=5.74,P=.013)。
关键数值与推荐
- CEBPA突变:β=2.26,HR=9.54,P=.003。
- EZH2突变:β=1.12,HR=3.062,P=.009。
- NRAS突变:β=1.29,HR=3.63,P=.048。
- U2AF1突变:β=1.75,HR=5.74,P=.013。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare myeloid disorders that are challenging with regard to diagnosis and clinical management. To study the similarities and differences between these disorders, we undertook a multicenter international study of one of the largest case series (CNL, n = 24; aCML, n = 37 cases, respectively), focusing on the clinical and mutational profiles (n = 53 with molecular data) of these diseases. We found no differences in clinical presentations or outcomes of both entities. As previously described, both CNL and aCML share a complex mutational profile with mutations in genes involved in epigenetic regulation, splicing, and signaling pathways. Apart from CSF3R, only EZH2 and TET2 were differentially mutated between them. The molecular profiles support the notion of CNL and aCML being a continuum of the same disease that may fit best within the myelodysplastic/myeloproliferative neoplasms. We identified 4 high-risk mutated genes, specifically CEBPA (β = 2.26, hazard ratio [HR] = 9.54, P = .003), EZH2 (β = 1.12, HR = 3.062, P = .009), NRAS (β = 1.29, HR = 3.63, P = .048), and U2AF1 (β = 1.75, HR = 5.74, P = .013) using multivariate analysis. Our findings underscore the relevance of molecular-risk classification in CNL/aCML as well as the importance of CSF3R mutations in these diseases.
引用
- Carreño-Tarragona G, Álvarez-Larrán A, Harrison C, et al. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Blood Adv. 2023. PMID: 36375042. doi:10.1182/bloodadvances.2022008204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。